Thrombophilia and its treatment in pregnancy

Journal of Thrombosis and Thrombolysis

Volumn 12, Issue 1, 2001, Pages 23-30

  Eldor, A ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Low molecular weight heparin; Obstetric complications; Pregnancy; Thrombophilia; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CORTICOSTEROID; DALTEPARIN; ENOXAPARIN; FOLIC ACID; HEPARIN; IMMUNOGLOBULIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; WARFARIN;

ANAMNESIS; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; BLOOD VESSEL; CESAREAN SECTION; CLINICAL TRIAL; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DOSE CALCULATION; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DRUG TRANSPORT; DRUG USE; FETOTOXICITY; FIRST TRIMESTER PREGNANCY; GENETIC DISORDER; HUMAN; HYPERHOMOCYSTEINEMIA; INDUSTRIALIZATION; INTRAUTERINE GROWTH RETARDATION; LONG TERM CARE; LUNG EMBOLISM; MATERNAL MORTALITY; OBESITY; OSTEOPOROSIS; PLACENTA; PREECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PROPHYLAXIS; PUERPERIUM; RECURRENT ABORTION; RISK; SOLUTIO PLACENTAE; STILLBIRTH; STROKE; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOPHILIA; TREATMENT OUTCOME;

ANTICOAGULANTS; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; THROMBOPHILIA; THROMBOSIS;

EID: 0035183248     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012730325902     Document Type: Conference Paper

References (77)

1. Epidemiology, risk factors and prophylaxis of venous thrombo-embolism in obstetrics and gynaecology
2. Thrombosis in pregnancy: Maternal and fetal issues
3. Recurrence of venous thromboembolism and the use of oral contraceptives
4. An ultrasound study of gestational and postural changes in the deep venous system of the leg in pregnancy
5. Venous thrombosis during pregnancy: Leg and trimester of presentation
6. The challenge of thrombophilia in maternal-fetal medicine
7. Thrombophilia as a multigenic disorder
8. Prothrombin and Factor V mutations in women with a history of thrombosis during pregnancy and the puerperium
9. Molecular genetics of venous thromboembolism
10. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: Study of 78 women
11. Thrombosis during pregnancy and surgery in patients with congenital deficiency of antithrombin III, protein C, protein S
12. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy
13. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase
14. Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy
15. Arg506-Gln mutation in Factor V and risk of thrombosis during pregnancy
16. Prothrombin 20210 G→A, MTHFR C677T mutations in women with venous thromboembolism associated with pregnancy
17. Factor V Q506 mutation (activated protein C resistance) associated with reduced intrapartum blood loss - A possible evolutionary selection mechanism
18. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis
19. Stroke and intracranial venous thrombosis during pregnancy and puerperium
20. Stroke in pregnancy and the puerperium
21. Pregnancy and the risk of stroke
22. Systemic lupus erythematosus and antiphospholipid syndrome during pregnancy: Maternal and fetal complications and their management
23. Ischemic stroke in young women: Risk of recurrence during subsequent pregnancies. French Study Group on Stroke in Pregnancy
24. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives
25. Transient focal neurological deficits during pregnancy in carriers of inherited thrombophilia
26. Intrauterine growth restriction in infants of less than thirty-two weeks' gestation: Associated placental pathologic features
27. Increased frequency of genetic thrombophilia in women with complications of pregnancy
28. Severe preeclampsia and high frequency of genetic thrombophilic mutations
29. Hyperhomocysteinemia and other thrombotic risk factors in women with placental vasculopathy
30. Plasma total homocysteine and previous pregnancies: The Hordaland homocysteine study
31. Placental thrombosis and second trimester miscarriage in association with activated protein C resistance
32. Factor V Leiden, C > T MTHFR polymorphism and genetic susceptibility to preeclampsia
33. Fetal carriers of the Factor V Leiden mutation are prone to miscarriage and placental infarction
34. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses
35. Activated protein C resistance can be associated with recurrent fetal loss
36. Thrombophilic polymorphisms are common in women with fetal loss without apparent cause
37. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin
38. Increased fetal loss in women with heritable thrombophilia
39. Factor V Leiden mutation as a risk Factor for recurrent pregnancy loss
40. Activated protein C resistance (FV:Q506) and pregnancy
41. Mutations in coagulation factors in women with unexplained late fetal loss
42. Prothrombin 20210 GA mutation analysis in Caucasian women with early first trimester recurrent pregnancy loss
43. Heridatary thrombophilia as a cause of fetal loss
44. Fetal neonatal outcome of exposure to anticoagulants during pregnancy
45. The congenital warfarin syndrome
46. Venous thromboembolism in pregnancy
47. The treatment of thrombosis during pregnancy
48. Low-molecular-weight heparin for obstetric thromboprophylaxis: Experience of sixty-nine pregnancies in sixty-one at high risk
49. Use of anticoagulants during pregnancy
50. Use of antithrombotic agents during pregnancy
51. Use of low molecular weight heparin for prophylaxis and treatment of thromboembolism in pregnancy
52. Use of low molecular weight heparin in pregnancy
53. Low molecular weight heparins and their use in obstetrics and gynecology
54. Thromboprophylaxis with low molecular weight heparin (fragmin) in high risk pregnancies
55. Low-molecular-weight heparin for obstetric thromboprophylaxis: Experience of sixty-nine pregnancies in sixty-one women at high risk
56. Safety of low-molecular-weight heparin in pregnancy: A systematic review
57. Lack of anti-factor Xa activity in umbilical cord vein samples after subcutaneous administration of heparin or low molecular mass heparin in pregnant women
58. Anticoagulants and spinal-epidural anesthesia
59. Risk of combining low molecular weight heparin for thromboprophylaxis and epidural or spinal anesthesia
60. Applying risk assessment models in non-surgical patients: Effective risk stratification
61. Management of pregnancy in women with thrombophilia
62. Safety of withholding heparin in pregnant women with a history of venous thromboembolism
63. A study of sixty pregnancies in patients with the antiphospholipid syndrome
64. Treatment of antiphospholipid syndrome in pregnancy
65. Thromboprophylaxis in antiphospholipid syndrome pregnancies with previous cerebral arterial thrombotic events: Is warfarin preferable?
66. Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units
67. A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss with lower dose heparin and aspirin
68. Use of low-molecular-weight heparin (enoxaparin) or of a phenformin-like substance (moroxydine chloride) in primary early recurrent aborters with an impaired fibrinolytic capacity
69. Inherited thrombophilia and pregnancy loss
70. The effect of thrombophylaxis on pregnancy outcome in patients with recurrent pregnancy loss associated with Factor V Leiden mutation
71. Low-molecular-weight heparin for thrombophilia in pregnant women
72. Low molecular weight heparin for the prevention of obstetric complications in women with thrombophilia
73. Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: A preliminary study
74. Antiphospholipid antibody-associated recurrent pregnancy loss: Treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone
75. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)
76. A multi-center, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy